Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases (SARC-ENDO)

Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.

.

Study Overview

• Status: Recruiting
• Conditions: Metabolic Diseases; Diabetes; Sarcopenia; Cushing Syndrome; Sarcopenic Obesity; Endocrine Diseases; Obesity & Overweight
• Intervention / Treatment: Drug: GLP-1 Receptor Agonists

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Laura Orioli, MD, PhD; Phone Number: +32494507621; Email: laura.orioli@saintluc.uclouvain.be

Study Locations

• Belgium
  • Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Belgium, 1150
    • Recruiting
    • Cliniques universitaires Saint-Luc
    • Contact: Laura Orioli, MD, PhD; Phone Number: +32494507621; Email: laura.orioli@saintluc.uclouvain.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

People with metabolic or endocrine diseases

Description

Inclusion Criteria:

• Metabolic or endocrine disease

Exclusion Criteria:

• Known myopathy
• Systemic steroid use (> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome
• Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol
• History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Prevalence of sarcopenia / sarcopenic obesity	From February 2026 to december 2056

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Myokines levels in serum or plasma	Myokines levels in serum or plasma as measured by ELISA	February 2026 to December 2056
Myokine expression	Myokine expression in muscle as measured by RT-qPCR or RNA-Seq	February 2026 to December 2056
Prevalence of MASLD	MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis	March 2026 to December 2056
Prevalence of MASH	Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis	March 2026 to December 2056

Collaborators and Investigators

• Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Study record dates

Study Major Dates

• Study Start (Actual): February 19, 2026
• Primary Completion (Estimated): December 31, 2056
• Study Completion (Estimated): December 31, 2056

Study Registration Dates

• First Submitted: May 15, 2026
• First Submitted That Met QC Criteria: July 10, 2026
• First Posted (Actual): July 14, 2026

Study Record Updates

• Last Update Posted (Actual): July 14, 2026
• Last Update Submitted That Met QC Criteria: July 10, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Neuromuscular Manifestations; Nutrition Disorders; Pathological Conditions, Anatomical; Overnutrition; Body Weight; Glucose Metabolism Disorders; Adrenal Gland Diseases; Muscular Atrophy; Atrophy; Adrenocortical Hyperfunction; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Overweight; Obesity; Diabetes Mellitus; Sarcopenia; Metabolic Diseases; Endocrine System Diseases; Cushing Syndrome; Physiological Effects of Drugs; Hypoglycemic Agents; Pharmacologic Actions; Chemical Actions and Uses; Glucagon-Like Peptide-1 Receptor Agonists
• Other Study ID Numbers: 2025/29OCT/445

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No